Companies:
49,811
Total Market Cap:
139366002746094.05
Global Rank
#813
Country Rank
#32
Market Cap
27.09 B
Price
110
Change (%)
1.61%
Volume
613,691
BioNTech SE's latest marketcap:
27.09 B
As of 07/04/2025, BioNTech SE's market capitalization has reached $27.09 B. According to our data, BioNTech SE is the 813th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 27.09 B |
| Revenue (ttm) | 2.97 B |
| Net Income (ttm) | -827,929,096 |
| Shares Out | 246.24 M |
| EPS (ttm) | -3.45 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/04/2025 |
Market Cap Chart
Data Updated: 07/04/2025
BioNTech SE's yearly market capitalization.
BioNTech SE has seen its market value grow from $19.63 B to $27.09 B since 2020, representing a total increase of 37.99% and an annual compound growth rate (CAGR) of 7.40%.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/04/2025 | $27.09 B | -0.85% | 813 |
| 12/31/2024 | $27.32 B | 8.89% | 703 |
| 12/29/2023 | $25.09 B | -31.28% | 721 |
| 12/30/2022 | $36.51 B | -41.37% | 446 |
| 12/31/2021 | $62.26 B | 217.21% | 282 |
| 12/31/2020 | $19.63 B | 890 |
Company Profile
About BioNTech SE
BioNTech SE is a pioneering biotechnology company based in Mainz, Germany, specializing in the development and commercialization of immunotherapies for cancer and infectious diseases.
Key Product Pipeline
- BNT111: Phase 2 clinical trial for advanced melanoma
- BNT113: Phase 2 clinical trial for head and neck squamous cell carcinoma
- BNT116: Phase 1 clinical trial for non-small cell lung cancer
- BNT142: Phase 1/2 clinical trial for multiple solid tumors
- BNT151: Phase 1/2 clinical trial for solid tumors
- BNT152 + BNT153: Phase 1 clinical trial for solid tumors
- BNT122/RO7198457: Phase 2 clinical trial for adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, and advanced melanoma
Additional Clinical Trials
- BNT211: Phase 1 for CLDN6+ solid tumors
- BNT221: Phase 1 for cancer treatment
- BNT311/GEN1046 (acasunlimab): Phase 3 for solid tumors
- BNT312/GEN1042: Phase 1/2 and 1 for solid tumors
- BNT314/GEN1059: Phase 1/2 for advanced/metastatic solid tumors
- BNT316/ONC-392: Phase 1/2, 2, and 3 for metastatic non-small cell lung cancer, platinum-resistant ovarian cancer, and other advanced tumors
Founded in 2008, BioNTech SE continues to lead innovation in immunotherapy, addressing some of the most challenging medical conditions worldwide.
Frequently Asked Questions
-
What is BioNTech SE's (BNTX) current market cap?As of 07/04/2025, BioNTech SE (including the parent company, if applicable) has an estimated market capitalization of $27.09 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does BioNTech SE (BNTX) rank globally by market cap?BioNTech SE global market capitalization ranking is approximately 813 as of 07/04/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.